Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant

Bone Marrow Transplantation

Volumn 34, Issue 8, 2004, Pages 721-727

  Eapen, M ^a   Giralt, S A ^b   Horowitz, M M ^a   Klein, J P ^a   Wagner, J E ^c   Zhang, M J ^a   Tallman, M S ^d   Marks, D I ^e   Camitta, B M ^a   Champlin, R E ^b   Ringden O ^f   Bredeson, C N ^a   Martino, R ^g   Gale, R P ^h   Cairo, M S ⁱ   Litzow, M R ^j   deLima, M ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^h Center for Advanced Studies in Leukemia   (United States)

ⁱ Och Spine at New York Presbyterian Hospitals   (United States)

^j MAYO CLINIC ROCHESTER   (United States)

more..

Author keywords

Duration of remission; Leukemia; Matched related donor; Reduced intensity conditioning regimen; Second transplantation

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; FLUDARABINE; MELPHALAN; METHOTREXATE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROBABILITY; RECURRENCE RISK; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 6444220659     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704645     Document Type: Article

References (32)

1. Mrsic M, Horowitz MM, Atkinson K et al. Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant 1992; 9: 269-275.
2. Kumar L. Management of relapse after allogeneic bone marrow transplantation. J Clin Oncol 1994; 7: 50-57.
3. Bosi A, Laszlo D, Labopin M et al. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European cooperative group for blood and marrow transplantation. J Clin Oncol 2001; 9: 3675-3684.
4. Mackinnon S, Papadopoulos EB, Carabasi MH et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-host disease. Blood 1995; 86: 1261-1268.
5. Bacigalupo A, Soracco M, Vassallo F et al. Donor lymphocyte infusion (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 19: 927-932.
6. Collins RH, Shpilberg O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15 433-444.
7. Dazzi F, Szydlo R, Goldman J et al. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: Where we now stand. Exp Haematol 1999; 27: 1477-1486.
8. Dazzi F, Szydlo RM, Cross NCP et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000; 96: 2712-2716.
9. Porter DL, Collins RH, Hardy C et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000; 95: 1214-1221.
10. Carlens S, Remberger M, Ascham J, Ringdén O. The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse. Biol Blood Marrow Transplant 2001; 7: 31-38.
11. Levine JE, Braun T, Penza SL et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem cell transplant. J Clin Oncol 2000; 20: 405-412.
12. Kantarjian HM, O'Brien S, Cortes JE et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2000; 100: 1590-1595.
13. Barrett AJ, Locatelli F, Treleaven JG et al. Second transplants for leukemic relapse after bone marrow transplantation: high early mortality but favorable effect of chronic GVHD on continued remission. Br J Haematol 1991; 79: 567-574.
14. Wagner JE, Vogelsang GB, Zehnbauer BA et al. Relapse of leukemia after bone marrow transplantation: effect of second myeloabalative therapy. Bone Marrow Transplant 1992; 9: 205-209.
15. Radich JP, Sanders JE, Buckner CD et al. Second allogeneic transplantation for patients with recurrent leukemia after initial transplantation with total body irradiation-containing regimen. J Clin Oncol 1993; 11: 304-313.
16. Martino R, Badell I, Brunet S et al. Second bone marrow transplantation for leukemia in untreated relapse. Bone Marrow Transplant 1994; 14: 589-593.
17. Chaing K-Y, Weisdorf DJ, Davies SM et al. Outcome of second bone marrow transplantation following a uniform conditioning regimen as therapy for malignant relapse. Bone Marrow Transplant 1996; 17: 39-42.
18. Bosi A, Bacci S, Miniero R et al. Second allogeneic bone marrow transplantation in acute leukemia: a multicenter study from the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). Leukemia 1997; 11: 420-424.
19. Kishi K, Takahashi S, Gondo H et al. Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes. Bone Marrow Transplant 1997; 19: 461-466.
20. Michallet M, Tanguy ML, Socie G et al. Second allogeneic heamtopoietic transplantation in relapsed acute and chronic leukemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de Moelle (SFGM). Br J Haematol 2000; 108: 400-407.
21. Tomonari A, Iseki T, Ooi J et al. Second allogeneic hematopoietic stem cell transplantation for leukemia relapse after first allogeneic transplantation: outcome of 16 patients in a single institution. Int J Hematol 2002; 75: 318-323.
22. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-identical sibling donors. Transplantation 1974; 18: 295-304.
23. Przepiorka D, Weisdorf D, Martin P et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
24. Atkinson K, Horowitz MM, Gale RP et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990; 75: 2459-2464.
25. Klein JP, Moeschberger ML. Survival Analysis: Techniques of Censored and Truncated Data. Springer-Verlag: New York, NY, 2003.
26. Cox DR. Regression models and life tables. J R Stat Soc Ser B 1972; 34:187-202.
27. Andersen PK, Klein JP, Zhang M-J. Testing for center effects in multi-center survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med 1999; 18: 1489-1500.
28. Clark TG, Altman DG, De Stavola BL. Quantification of the completeness of follow up. Lancet 2001; 359: 1309-1310.
29. Giralt S, Estey E, Albitar et al. Engraftment of allogeneic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
30. Pawson R, Potter MN, Theocharous P et al. Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG ± Ida) and second allogeneic stem cell transplant. Br J Haematol 2001; 115: 622-629.
31. Champlin RE, Schmitz N, Horowitz MM et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 2000; 95: 3702-3709.
32. Bensinger WI, Martin PJ, Storer B et al. Transplantation of bone marrow as compared with peripheral blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175-181.